Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
This is a summary aggregated from CNBC. Read the complete article on the original site:
Read full article at CNBC
